Related Experiment Videos
[Action of calcium dobesilate on capillary fragility in diabetics]
Archivio Per Le Scienze Mediche
|July 1, 1977
Insights
Calcium dobesylate effectively treated diabetic microangiopathy and capillary fragility in 90% of patients. This drug shows promise for preventing systemic microangiopathy and managing diabetic retinopathy.
Area of Science:
- Vascular biology
- Endocrinology
- Pharmacology
Context:
- Diabetic microangiopathy is a common complication of diabetes mellitus.
- Increased capillary fragility is a hallmark of diabetic microangiopathy.
- Current treatments for diabetic microangiopathy have limitations.
Purpose:
- To evaluate the efficacy of calcium dobesylate in patients with diabetic microangiopathy and increased capillary fragility.
- To assess the safety and tolerability of calcium dobesylate in this patient population.
Summary:
- Calcium dobesylate was administered for 30 days to diabetic patients with or without clinical signs of microangiopathy and increased capillary fragility.
- No coagulation or hemostasis disturbances were observed.
- Good results were achieved in 90% of the cases.
Impact:
- Calcium dobesylate demonstrates significant potential for the tertiary prevention of systemic microangiopathy.
- The drug may serve as a valuable therapeutic option for the medical management of diabetic retinopathy.
Abstract:
Calcium dobesylate was administered for 30 days to diabetics with or without clinical signs referable to microangiopathy and increased capillary fragility unaccompanied by coagulation and haemostasis disturbances. Good results were observed in 90% of cases. It is felt that the drug can also be used in the tertiary prevention of systemic microangiopathy, as well as the medical management of diabetic retinopathy.